Cargando…
Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients’ gut microbiota, characterized by a decreased abund...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419057/ https://www.ncbi.nlm.nih.gov/pubmed/37569625 http://dx.doi.org/10.3390/ijms241512249 |
_version_ | 1785088419055009792 |
---|---|
author | Martín Giménez, Virna Margarita Modrego, Javier Gómez-Garre, Dulcenombre Manucha, Walter de las Heras, Natalia |
author_facet | Martín Giménez, Virna Margarita Modrego, Javier Gómez-Garre, Dulcenombre Manucha, Walter de las Heras, Natalia |
author_sort | Martín Giménez, Virna Margarita |
collection | PubMed |
description | Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients’ gut microbiota, characterized by a decreased abundance of bacteria with probiotic effects. Interestingly, certain strains of these bacteria produce metabolites that can target the S protein of other coronaviruses, thereby preventing their transmission and harmful effects. At the same time, the presence of gut dysbiosis can exacerbate inflammation and oxidative stress, creating a vicious cycle that perpetuates the disease. Furthermore, it is widely recognized that the gut microbiota can metabolize various foods and drugs, producing by-products that may have either beneficial or detrimental effects. In this regard, a decrease in short-chain fatty acid (SCFA), such as acetate, propionate, and butyrate, can influence the overall inflammatory and oxidative state, affecting the prevention, treatment, or worsening of COVID-19. This review aims to explore the current evidence regarding gut dysbiosis in patients with COVID-19, its association with inflammation and oxidative stress, the molecular mechanisms involved, and the potential of gut microbiota modulation in preventing and treating SARS-CoV-2 infection. Given that gut microbiota has demonstrated high adaptability, exploring ways and strategies to maintain good intestinal health, as well as an appropriate diversity and composition of the gut microbiome, becomes crucial in the battle against COVID-19. |
format | Online Article Text |
id | pubmed-10419057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104190572023-08-12 Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy Martín Giménez, Virna Margarita Modrego, Javier Gómez-Garre, Dulcenombre Manucha, Walter de las Heras, Natalia Int J Mol Sci Review Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients’ gut microbiota, characterized by a decreased abundance of bacteria with probiotic effects. Interestingly, certain strains of these bacteria produce metabolites that can target the S protein of other coronaviruses, thereby preventing their transmission and harmful effects. At the same time, the presence of gut dysbiosis can exacerbate inflammation and oxidative stress, creating a vicious cycle that perpetuates the disease. Furthermore, it is widely recognized that the gut microbiota can metabolize various foods and drugs, producing by-products that may have either beneficial or detrimental effects. In this regard, a decrease in short-chain fatty acid (SCFA), such as acetate, propionate, and butyrate, can influence the overall inflammatory and oxidative state, affecting the prevention, treatment, or worsening of COVID-19. This review aims to explore the current evidence regarding gut dysbiosis in patients with COVID-19, its association with inflammation and oxidative stress, the molecular mechanisms involved, and the potential of gut microbiota modulation in preventing and treating SARS-CoV-2 infection. Given that gut microbiota has demonstrated high adaptability, exploring ways and strategies to maintain good intestinal health, as well as an appropriate diversity and composition of the gut microbiome, becomes crucial in the battle against COVID-19. MDPI 2023-07-31 /pmc/articles/PMC10419057/ /pubmed/37569625 http://dx.doi.org/10.3390/ijms241512249 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Martín Giménez, Virna Margarita Modrego, Javier Gómez-Garre, Dulcenombre Manucha, Walter de las Heras, Natalia Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy |
title | Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy |
title_full | Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy |
title_fullStr | Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy |
title_full_unstemmed | Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy |
title_short | Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy |
title_sort | gut microbiota dysbiosis in covid-19: modulation and approaches for prevention and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419057/ https://www.ncbi.nlm.nih.gov/pubmed/37569625 http://dx.doi.org/10.3390/ijms241512249 |
work_keys_str_mv | AT martingimenezvirnamargarita gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy AT modregojavier gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy AT gomezgarredulcenombre gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy AT manuchawalter gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy AT delasherasnatalia gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy |